Bencyclane
Top View
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Marrakesh Agreement Establishing the World Trade Organization
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2016) Annotated for Statistical Reporting Purposes
- Mining of High Throughput Screening Database Reveals AP-1 And
- Peripheral Arterial Disease
- 'Cerebroactive' Drugs Clinical Pharmacology and Therapeutic Role in Cerebrovascular Disorders
- Bencyclane — a New Aspect of the Mechanism of Action in Patients with Peripheral Arterial Occlusive Disease
- Pharmaabkommen A1 E
- Evidence Review E: Postnatal Management of Hypertension
- Pharmaceutical Appendix to the Tariff Schedule 2
- Customs Tariff - Schedule Xxi - 1
- United States Patent (19) 11 Patent Number: 5,811,547 Nakamichi Et Al
- First-Line Combination Therapy Versus First-Line Monotherapy for Primary Hypertension (Review)
- Bencyclane Fumarate (Rinnm) Rinogenic in Animals Or In-Vitro Systems
- Pharmaceutical Appendix to the Tariff Schedule 2
- Harmonized Tariff Schedule of the United States (2006) (Rev
- Customs Tariff - Schedule Xxi - 1